New hospital EBITDA drag continuing in Q3
Delhi and Faridabad Sector 20 hospitals will continue to drag EBITDA in Q3 similar to Q2 levels (~3.3% overall margin dilution), with break-even targeted in 15-17 months.
YATHARTH / bear-case history
Track the concerns that keep returning.
Yatharth Hospital & Trauma Care Services · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
medium
Jansi occupancy growth depressing blended ARPO
Jansi hospital reaching 70% occupancy (ARPO roughly half of group average) is muting overall ARPO growth despite mature hospital ARPO growth of 9% YoY.
Working capital and receivables cycle
Data days reduced by 8-10 days this quarter; OCF to EBITDA at 58% impacted by salary payment timing change, expected to normalize to ~78% by March 2026.
Agra acquisition integration timeline
Analyst asked about when Agra results would appear in books (Q4 confirmed), but integration execution risk exists given it is an existing running hospital being acquired mid-fiscal.
New hospital operational drag may pressure near-term margins
Delhi and Faridabad Sector 20 incurred ~₹20 crore combined losses in Q3. While management expects breakeven within 12-15 months, losses may widen before stabilizing as capacity expansion continues with 300-bed Delhi and 400-bed Faridabad Sector 20 full operationalization.
Extended receivables from government/ESI schemes
Analyst questioned why Yatharth's government receivables (~200+ days) exceed listed peers (sub-150 days). Management attributed this to 35% ESI exposure (30-40% of government business), which has slower payment cycles than standard CGHS. Collections improvement initiatives underway but government mix remains a working capital headwind.
Competitive intensity in Noida catchment
Analyst raised concerns about new hospital chain entry in Noida region. Management responded that competition validates the territory's attractiveness but did not quantify market share impact or respond to the specific competitive threat question with concrete mitigation steps beyond 'clinical excellence' positioning.
IT/Litigation matter resolution timeline ambiguous
When pressed on specific timeline for complete resolution of the IT/litigation matter mentioned in prior quarters, management stated 'very soon' and 'coming quarters' without committing to a specific quarter. This evasive response leaves uncertainty around potential contingent liabilities or operational disruptions.